Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
We will retrospectively enroll patients diagnosed with advanced or metastatic gastric cancer at the Department of Medical Oncology and Radiation Sickness of Peking University Third Hospital. The retrospective study aims to investigate the impact of bleeding on treatment-related adverse events (TRAEs) for gastric cancer patients receiving systematic anticancer treatment, assess the influence of bleeding on the survival of patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test group | Gastirc cancer with bleeding at first diagnosis |
| |
| Control group | Gastirc cancer without bleeding at first diagnosis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| systematic therapy | Drug | All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival (OS) | OS was defined as the time from the first cycle of systematic therapy to death from any cause. | from date of the first cycle of systematic therapy to death from any cause，assessed up to 120 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Advanced or metastatic gastric cancer at the Department of Medical Oncology and Radiation Sickness of Peking University Third Hospital.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yanhong Yao | Contact | +86 010-82265857 | snowdream246@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Yanhong Yao | Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40747247 | Derived | Yao Y, Liu Z, Zhang H, Shi X, Huang F, Zhang Y, Chen L, Shi Y, Cao B. Feasibility of systemic therapy in unresectable gastric/gastroesophageal junction cancer with overt bleeding. Asia Pac J Oncol Nurs. 2025 Jul 7;12:100750. doi: 10.1016/j.apjon.2025.100750. eCollection 2025 Dec. |
Not provided
Not provided
The datasets analyzed during the study are available on reasonable request.
After the trial is completed
Used for scientific research
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jul 18, 2024 | Jul 19, 2024 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D013274 | Stomach Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D000082082 | Immune Checkpoint Inhibitors |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D004066 |
| Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |
| D000074322 | Antineoplastic Agents, Immunological |
| D000970 | Antineoplastic Agents |
| D045506 | Therapeutic Uses |